Save Product
Product Details
Source
Monoclonal Anti-Payload PBD Antibody, Rabbit IgG (1M1F9) is a rabbit monoclonal antibody recombinantly expressed in HEK293 cells.
Antibody Type
Recombinant Monoclonal
Clone
1M1F9
Isotype
Rabbit IgG, Kappa
Immunogen
PBD-BSA
Specificity
Specifically recognizes PBD.
Purification
Protein A purified / Protein G purified.
Concentration
Please refer to the Certificate of Analysis (CoA).
Form
Lyophilized
Formulation
Lyophilized from a 0.22 μm-filtered solution in PBS (pH 7.4), with trehalose as protectant.
Please contact us for customized product forms or formulations.
Reconstitution
Please refer to the Certificate of Analysis (CoA) for specific instructions.
Shipping
Lyophilized product is shipped at ambient temperature.
Storage
For long term storage, the product should be stored in a lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
Notices
Product Specific Notices: For research use only.
ACRO Quality Management System
Customers Also Viewed
Performance Data
Bioactivity-ELISA
Immobilized Monoclonal Anti-Payload PBD Antibody, Rabbit IgG (1M1F9) (Cat. No. PAD-MY2212) at 1 μg/mL, add Loncastuximab Tesirine in the 100% Human Serum and then add Biotinylated Human CD19 (20-291), His,Avitag, premium grade (Cat. No. CD9-H82E9) at 0.5 μg/mL. Detection was performed using HRP-conjugated Streptavidin (Acro, Cat. No. STN-NH913) (QC tested).
Protocol
Serial dilutions of (PBD)SG3199 were added into Monoclonal Anti-Payload PBD Antibody, Rabbit IgG (1M1F9) (Cat. No. PAD-MY2212)): Loncastuximab Tesirine binding reactions. The half maximal inhibitory concentration (IC50) is 0.02167 μg/mL (Routinely tested).
Protocol
Cross Verification
ELISA binding of Monoclonal Anti-Payload PBD Antibody, Rabbit IgG (1M1F9) (Cat. No. PAD-MY2212) with Loncastuximab Tesirine, Disitamab Vedotin (RC48), IgG1-MMAF, Trastuzumab Deruxtecan, Sacituzumab Govitecam and Trastuzumab-DM1 conjugated antibody respectively.
The coating antibody was Monoclonal Anti-Payload PBD Antibody, Rabbit IgG (1M1F9) (Cat. No. PAD-MY2212), used at 1 μg/mL concentration. The primary antibody were different payload conjugated antibodies, including Loncastuximab Tesirine, Disitamab Vedotin (RC48), IgG1-MMAF, Trastuzumab Deruxtecan, Sacituzumab Govitecam and Trastuzumab-DM1 conjugated antibodies used at 0.25 μg/mL concentration. The secondary antibody was HRP conjugated Anti-Human-IgG-Fc Antibody (6F11C8), mAb (Acro, Cat. No. IGG-LY69) used at 1:10000 concentration.
Monoclonal Anti-Payload PBD Antibody, Rabbit IgG (1M1F9) (Cat. No. PAD-MY2212) is specific to Loncastuximab Tesirine and has no cross-reactivity with IgG1-MMAF, Disitamab Vedotin (RC48), Trastuzumab Deruxtecan, Sacituzumab Govitecam and Trastuzumab-DM1 (Routinely tested).
Customer Reviews Writing Reviews
Background
Recent Advances
Contact Us
전화
글로벌: +1 800-810-0816 (무료)
아시아태평양: +86 400-682-2521
Drug Candidate Licensing
